March 5, 2018 / 12:18 PM / 3 months ago

BRIEF-Prometic Receives Rare Pediatric Disease Designation From U.S. FDA For Its Inter-Alpha-Inhibitor-Proteins

March 5 (Reuters) - Prometic Life Sciences Inc:

* PROMETIC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM U.S. FDA FOR ITS INTER-ALPHA-INHIBITOR-PROTEINS

* PROMETIC LIFE SCIENCES INC - IN ADDITION TO RARE PEDIATRIC DISEASE DESIGNATION, IAIP HAS ALSO BEEN GRANTED AN ORPHAN DRUG DESIGNATION BY FDA

* PROMETIC LIFE SCIENCES - COSTS ASSOCIATED WITH CLINICAL PROGRAM RELATED TO THE PEDIATRIC & ORPHAN DRUG DESIGNATIONS “WILL NOT IMPACT OUR FY2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below